Repros Reports Preliminary Findings: Second Pivotal Study And 6-Month Safety Study Support Androxal(R) Approvability

  • Androxal meets both co-primary endpoints in second pivotal study ZA-302
  • Testosterone normalized in 81% of patients
  • No deleterious effects on sperm function
  • No excursions above normal in 24 hour average testosterone
  • Androxal is generally well tolerated in 6 month safety study ZA-300
  • No dose dependent adverse events
  • Adverse event profile similar or superior to other approved testosterone therapies with over 90% of safety database collected
  • NDA submission on track

THE WOODLANDS, Texas, Sept. 16, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today reported topline results from both the second pivotal efficacy study as well as the 6 month safety study of Androxal ® in the treatment of men with secondary hypogonadism. Secondary hypogonadism is the largest subset of hypogonadal men accounting for greater than 85% of the reported cases. Recent scientific publications, confirmed by Company experience, suggest obesity is the single greatest cause for hypogonadism. Subjects in all ongoing Androxal studies were required to exhibit morning testosterone (T) levels of <300 ng/dL on two separate consecutive mornings, be under 60 years of age and have a BMI over 25.

All men started at the lower 12.5 mg dose but up-titrated at any time during the study if their morning testosterone was < 450 ng/dL in the 6 month study and < 300 ng/dL in the efficacy study. The lower up-titration threshold was dictated by the FDA for the efficacy study. The Company believes a level of 450 ng/dL or higher will confer the desired clinical benefits of testosterone, including metabolic and quality of life improvements.

If you liked this article you might like

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

8 Stocks Under $10 to Trade for Huge Profits

5 Stocks Under $10 Set to Soar

Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results

4 Stocks Under $10 to Trade for Big Breakouts